The researchers report in the New England Journal of Medicinethat abelacimab, a Factor XI inhibitor, significantly reduced bleeding compared to a standard-of-care anticoagulant, rivaroxaban.
The results of the Regulation of Coagulation in Major Orthopedic Surgery Reducing the Risk of DVT and PE (RECORD) studies showed that rivaroxaban is more effective than enoxaparin in the ...
Hosted on MSN1mon
Anti-clotting drug significantly reduces bleeding events in patients with atrial fibrillation, clinical trial showsThe researchers report in the New England Journal of Medicine that abelacimab, a Factor XI inhibitor, significantly reduced bleeding compared to a standard-of-care anticoagulant, rivaroxaban.
The results of the Regulation of Coagulation in Major Orthopedic Surgery Reducing the Risk of DVT and PE (RECORD) studies showed that rivaroxaban is more effective than enoxaparin in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback